the application of cancer registries to cancer research. At its annual scientific meeting in Hamburg, FRG, in August 1990, the IACR adopted a policy statement on the provision of a legal basis for population-based cancer registries. The IACR statement included support for the principle that data concerning individuals with cancer should be strictly confidential, but noted that full respect for the confidentiality of such data need not prevent the safe, efficient and useful operation of cancer registries, as shown by worldwide experience over many years.
Need for individual data
It is important to stress both the value of population-based health research for the control and prevention of cancer (Parkin et al., 1985) and the essential nature of access to medical records with individually identifiable information in the conduct of such research. In testimony before a US congressional committee on government information and individual rights in 1979, for example, Gordis and Gold (1980) identified a number of major contributions to the understanding of disease, all derived from epidemiological studies in which individual medical records were used, either directly, or to identify subjects suitable for further study: some of the major advances involving cancer are listed in Table I . In assessing the challenge posed by current public health problems, especially cancer, they pointed out that 'the effects on human health of new drugs and other chemicals in the environment can only be identified through epidemiologic and other investigations, most of which depend on the availability of medical records'.
The US National Research Council recently set up a Panel on Confidentiality and Data Access to consider this issue. In inviting comments, the Panel emphasised 'the balance that must be struck between protecting the confidentiality of in- aAdapted from Gordis and Gold (1980) . formation provided by persons or businesses for statistical purposes and the need to make publicly-collected data widely available for legitimate research and statistical uses. ' The UK Medical Research Council (MRC) recently revised its 1972 statement on the principles and standards of practice expected of researchers who use personal medical data (MRC, 1985) . The MRC statement points out that doctors have a duty to build on the knowledge gained from treating patients; that medical advance often depends on pooling the experience of many doctors; and that 'advances made in this way are so important that the council believes that, provided every practical step has been taken to safeguard confidentiality and to ensure that no disadvantage, harm, distress or embarrassment is suffered by any individual as a consequence, there should be no impediment to the use of medical information in research'.
Effective cancer registration requires the collection and linkage of data about individuals with cancer, often from several different sources, over a number of years, from the diagnosis of the cancer until the death of the individual (Jensen et al., 1991) . It is essential that personal identifiers, including the individual's name and birthdate, be used in collecting these data, for the following reasons:
(a) to eliminate multiple counting of a single tumour (which would otherwise seriously inflate estimates of cancer occurrence in the population) by combining data about one individual from various sources at the time of initial cancer registration;
(b) to enable a tumour record to be completed with data obtained subsequently about recurrence, metastasis, new primary cancers, and death; (c) to ensure that data about individuals in the registry are accurate, and can be readily corrected or updated;
(d) to enable production of cancer survival statistics. By following up patients registered with cancer, or by matching cancer registrations with death certificates, it is possible to assess the survival of all persons with cancer in a defined population. Survival from cancer in the population as a whole is frequently different from survival in selected series of patients, such as those recruited to clinical trials. Cancer survival can also be assessed by clinical stage or extent of spread at diagnosis, by type of treatment or by other variables recorded at cancer registration, such as socioeconomic category (Karjalainen & Pukkala, 1990 ). This in turn enables definition of prognostic variables and the design of early detection and treatment campaigns; (e) to enable epidemiological studies of cancer to be carried out. The argument here closely parallels that underlying the notification of infectious diseases: it may only be possible to investigate infectious disease outbreaks effectively if identifiable individual case reports of the disease are available. To investigate possible causes of cancer, for example in case control studies, it is often necessary to contact patients to obtain information on past exposure to chemicals or other agents which may have caused their cancer.
The IACR statement notes that adequate safeguards for the individual's right to privacy can be obtained by adherence to an appropriate code of conduct in the operation of the cancer registry, just as in the operation of surveillance systems for notifiable sexually transmitted diseases and other infectious diseases, or in the operation of hospital records systems. Administrative restrictions on cancer notificationsuch as the requirement that patients give written or verbal consent for data about their cancer to be entered into a registry -produce uncontrollable selection bias and distortion of incidence data which seriously detract from the usefulness of the data collected. (Table II) . Just over half (55%) of the registries obtain reports on a purely voluntary basis from physicians, hospitals and other institutions treating cancer patients. For some 38% of registries, reporting is required either by laws of the state or by local administrative regulations, while for the remaining seven per cent of registries, the legal basis of reporting is mixed, some sources being required to report all diagnosed cancers, while others cooperate on a voluntary basis. Of the 105 registries included in volume V of Cancer Incidence in Five Continents, covering the period 1978-1982, 62 (59%) relied on voluntary reporting. Among registries which had begun operation since 1970, the proportion was slightly higher (64%) (Muir et al., 1987) . There is thus no evidence of any major recent shift toward mandatory reporting of cancer. In the EEC, 85% of registries still received cancer notifications on a voluntary basis in 1987 (Coleman & Demaret, 1988) .
Where cancer is a disease that must be notified by law, the doctor or institution reporting the cancer to the registry will expect indemnity from legal action for breach of medical confidentiality; this may make it easier to encourage cooperation with cancer registration activities. Even where there is a legal requirement to report cancer, however, it is not easily enforceable, and there is little evidence that the mere existence of such a requirement can ensure completeness of registration, unless the necessary infrastructure for cancer registration is already in place. In the cancer registry of Finland, for example, reporting was voluntary until 1960, when it became compulsory: no difference was observed in the level of registration (Muir & Demaret, 1982) . By contrast, the legal requirement to report cancers to the Turkish Ministry of Health since 1983 has resulted in less than a quarter of the expected number of cancer registrations, whereas in Denmark, cancer registration was voluntary from 1943 onwards, and had been largely complete for many years before notification of cancer became obligatory in 1987.
Laws designed to protect individual privacy may have the additional but unintended effect of making effective cancer registration impossible: for example, the number of cancers reported to the cancer registry in Hamburg, FRG, fell from 10,000 a year to just two cases in 1980-1981, owing to apprehension among physicians about possible legal consequences of reporting cancers in their patients to the registry, following a change in the rules governing transfer of such information between the registry and the Ministry of Health (Muir & Demaret, 1991). Since 1985, a special law has allowed physicians to report cases of cancer to the registry, but subject to the patient's consent (Thiele, 1990): it will be some time before the effects of this legislation can be evaluated.
If legislation is required, it should enable efficient and confidential reporting of cancer. Such a law should explicitly state that a cancer patient either should be (mandatory) or may legally be (voluntary) reported and registered in an identifiable manner, but that confidentiality must be maintained. The precise legal framework for cancer registration will obviously vary between states, but it should provide both a statement of the principles underlying confidentiality in the cancer registry, and a practical mechanism for ensuring that these principles are observed.
A few examples may serve to demonstrate the range of approaches adopted in relation to confidentiality and the outcome for cancer registration practice: The national cancer registry of the ex-German Democratic Republic, the largest in Europe, has recorded detailed information on cancers arising in a population of 17 million since 1953, and has been a particularly rich source of data for research (see for example Haas et al., 1987) . Since the reunification of Germany in 1990, however, registration has ceased and the data are not currently available for research (Sietmann, 1991) , while a new legal basis is still being sought to permit both research with the existing data and continuation of cancer registration (Dickman, 1990) .
France
There are a number of regional population-based cancer registries, the earliest dating from 1975. Many produce valuable incidence data (Benhamou et al., 1988) . Such a register can be used to measure incidence and survival, but it is subject to the same problems of duplicates and selection bias as in the German cancer registries, and cannot be used as the starting point for epidemiological studies requiring access to data on individuals. The paradox has been further highlighted by an epidemiological study, not of cancer, but of the genetics of manic depression, in which 30,000 people have been identified as being at risk of a treatable form of hereditary chronic glaucoma, genetically linked to manic depression, and which if untreated can lead to blindness. The individuals are known by name to the researchers, who are prevented by law from warning them (Nau, 1991). Legislation apparently in preparation would resolve this difficulty by providing adequate controls on individual privacy at the same time as facilitating epidemiological research.
Guidelines on confidentiality
Guidelines on confidentiality are required for efficient and acceptable registration of cancer. The main objectives of such guidelines are (Muir, 1991):
(a) to ensure the protection of confidentiality of data about individuals whose cancer is reported to the registry, so that information on registered persons cannot reach unauthorised third parties;
(b) to ensure that cancer registry data are of the best possible quality;
(c) to ensure that the best possible use is made of cancer registry data for the benefit of cancer patients, for cancer control in the population, and for medical research.
The existence of a set of guidelines will not by itself ensure either high quality or effective use of the data, but such guidelines define both the conditions under which high quality data may be collected, linked and stored in an ethical manner, and a framework to ensure safe and effective use of the data in a manner consistent with ethical guidelines (Last, 1990) . A code of confidentiality will thus help to ensure that a proper balance can be struck between the individual's right of privacy and the right of the individual, and that of his or her fellow citizens, to benefit from the knowledge on cancer causation, prevention, treatment and survival that can be derived from cancer registration.
The existence of confidentiality guidelines, and evidence that they are respected in practice, may be necessary to reassure members of the public, especially cancer patients, that data stored in the cancer registry are treated according to standards of confidentiality that are at least as stringent as those used in the hospital or the physician's office, and that the use of these data for research purposes is covered by adequate safeguards. In some countries, such guidelines may need to be supported by law or regulation, and to specify sanctions in the event of breach of confidentiality, as well as a mechanism for monitoring the adequacy of data security procedures. Guidelines for confidentiality also provide registry directors with operational guidance, and protect the reporting physician or institution.
Some cancer registries expressed the need for model guidelines on confidentiality at the Hamburg meeting of IACR in 1990, even though most registries already have formal sets of rules for the maintenance of confidentiality of their data, often established in cooperation with the competent local authorities. The guidelines on confidentiality presented here (annex I) were originally prepared with the help of several IACR member cancer registries, a national vital statistics office and the EEC, and revised in the light of comments received from other IACR member registries. They have now been further revised and brought up to date, after circulation for comments to 325 cancer registries and individual members of IACR.
It should be stressed that these guidelines on confidentiality are not intended en bloc for adoption as a fixed set of rules by any particular cancer registry. The operating conditions of cancer registries vary greatly around the world, and a set of measures considered to be satisfactory in one cultural context and at a given period of time would prove inappropriate in another context: there is no simple, global solution to the problem posed by the maintenance of confidentiality. Instead, the guidelines are intended to outline some basic principles, and to provide a set of specific measures designed to ensure the preservation of confidentiality, from which a registry may select and reformulate, as necessary, those measures considered to be most useful in the preparation or revision of a local code of practice on confidentiality. The guidelines would need to be adapted to national or local circumstances; they should be used to complement rather than replace existing registry rules, and the resulting local code of practice on confidentiality would need to take account of local ethical practice.
An earlier version of the guidelines presented here has already been translated, adapted and incorporated in this way by a number of cancer registries and by a national AIDS register; it has also been used in the preparation of a training manual for cancer registry personnel in developing countries (IARC, in preparation). The earlier version was also adopted by the EEC Committee of Cancer Experts in May 1989 as the basis for its recommendation to the EEC Commission on guidelines for confidentiality in cancer registration.
The chief measures in the code of confidentiality for the operation of cancer registries are intended:
(a) to define what information is confidential; (b) to specify measures for the security of data within the cancer registry;
(c) to require surveillance and periodic review of data security procedures;
(d) to define the conditions under which confidential data held by the registry can be released to approved medical research workers;
(e) to protect the reporting physician and institution.
In their testimony to the US Congress, Gordis and Gold (1980) laid special emphasis on the point that 'investigations of the natural history of disease and of the effectiveness of preventive and therapeutic interventions are of great potential benefit to society, but the conduct of such studies requires that, with proper safeguards, individually identifiable data from medical records continue to be made accessible for medical and epidemiological research'. In a number of countries, there are now pressing demands both for an absolute ban on any transfer of personal medical information and for rapid identification and control of health hazards to the public. The inherent conflict between these two positions (sometimes, with scant regard for logic, adopted simultaneously) can certainly be resolved, but only if governments can ensure that regulations designed to safeguard the privacy of the individual are framed so as to permit -indeed to encourage -well-conceived research. With this background, the guidelines for confidentiality in cancer registration presented here are intended to be of value for the data subject, the data supplier and the data user. (data suppliers).
Background
The background to these guidelines is presented in the accompanying article, which should be read in conjunction with these guidelines. 
Use of aggregate data (a) Research
One of the most important contributions of the cancer registry is to provide current data on the incidence of various types of cancer, and on variations in incidence by age, sex, place of birth, occupation, ethnic group, etc. These data can also be used to study differences in histological types and between urban and rural areas, and to examine trends in incidence over time. Only aggregate, anonymous data are used in such studies.
(b) Health care planning Information provided by the cancer registry on the numbers of cancer patients can help health authorities in various ways, including long-term planning for the provision of medical facilities and the training of health care professionals; establishment of priorities and programmes for cancer control; evaluation of the effects of intervention; and estimation of the numbers of cancer patients in the future (projections). For all these purposes the identity of individual cancer patients is neither needed nor provided: only aggregate data are used.
Principles of confidentiality 4.1 Underlying concept of medical confidentiality
The set of principles outlined below relates to the preservation of confidentiality in connection with or during the process of collection, storage, use, and transmission of identifiable data by the cancer registry. A cancer registry must maintain the same standards of confidentiality in handling identifiable data as customarily apply to the doctor-patient relationship; this obligation extends indefinitely, even after the death of the patient.
These guidelines are intended to help ensure the confidentiality of data about individuals whose cancer is reported to the registry, so that information on registered persons cannot reach unauthorised third parties.
Sharing of confidential clinical information
For serious diseases such as cancer, 'in modern medical practice, the doctor can seldom be the sole confidant, since effective care involves others, both medical and non-medical, technical and clerical, who provide services and manage the health care institutions' (Medical Research Council, 1985) . Despite this essential dispersion of confidential information within the clinical team, ultimate responsibility for the maintenance of confidentiality remains with the treating physician. The treating physician who provides information to a cancer registry about a patient with cancer therefore has the right to expect that the registry observes strict rules of confidentiality (see section 5.1).
Legal protection of data suppliers
Unless cancer is a disease which must be notified to a cancer registry by virtue of a law or administrative order, the data recorded by the cancer registry are supplied on a voluntary basis by the physician or institution. In some countries, therefore, it may be necessary for the registry to ensure that there is at least legal authority for physicians to report cancer, in order to protect data suppliers from legal action for breach of confidentiality in submitting identifiable data to the cancer registry.
Confidentiality and utility
Effective operation of the cancer registry depends on the continuous supply of confidential information from several sources, notably clinicians, pathologists and vital statistics offices. These data suppliers can only be expected to continue to provide such information if the cancer registry can be trusted to maintain confidentiality and to make good use of the data. Data suppliers will therefore need to be satisfied that the registry adheres to an adequate set of guidelines on confidentiality, and that data of high quality are being collected and used for the benefit of cancer patients and cancer research.
Scope of confidentiality measures
Maintenance of the confidentiality of identifiable data held by the cancer registry should extend beyond information on cancer patients and those notifying them (data subjects and data suppliers), to include identifiable data from medical records, census data, interview records, death certificates and lists of members of industrial cohorts or other study populations which may be stored in or provided to the cancer registry as part of its routine operations or for research projects.
Confidentiality of data on deceased persons
Data on deceased persons held in the cancer registry should be subject to the same procedures for confidentiality as data on living persons, even though death certificates or related information may be available from other sources, or in the public domain.
Indirectly identifiable data
Individual records from which names and address have been removed, but from which it might still be possible to identify an individual indirectly by use of the remaining data, e.g. an identity number, should also be subject to the measures for preservation of confidentiality in the cancer registry.
Methods of data storage and transmission
Guidelines for the maintenance of confidentiality are applicable not only to the storage of identifiable data on computers, but also to the storage of such data in the form of paper records, microfilm, microfiche and magnetic media, and their transport or transmission by registry personnel in any of these formats. The Director of the registry should maintain an up-todate list of registry staff members indicating the type of data to which each of them has access (with the corresponding level of computer security, if relevant).
Display of reminders
It is recommended that notices reminding staff of the need to maintain confidentiality be prominently displayed within the registry.
Active registration
Registry staff assigned to collect information at source (active registration) are responsible for maintaining the confidentiality not only of identifiable data they may collect on persons with cancer for the registry, but also of other information of a confidential nature which they may read or hear at the source.
Cancer registries using active methods of registration should give consideration (a) to providing staff with a lockable attache-case for the transport of confidential information; (b) to advising staff on other measures to avoid accidental loss of such material; and (c) to pro-viding staff with suitable means of identification as an employee of the cancer registry. The identity of such staff should be made known to the relevant person(s) at each of the sources which they visit to collect information for the registry, and where possible, changes in personnel should be notified to these sources in advance.
Incomplete data
If it is necessary for the registry to request additional information from a source concerning a particular registration, for example to check an address or date of diagnosis, this should be done by sending a confidential enquiry to a named individual at the source concerned. One technique used by certain registries is to arrange for the computer to generate standardised requests for missing data items which are then mailed under confidential cover, or electronically.
Cases identified from death certificates
Comparison of registry files with death certificates may reveal a death certified as due to a cancer not apparently registered in life. Registries which seek further information about cases first identified from a death certificate should request information from the certifying physician or the vital statistics office, according to local circumstances; if no further information can be obtained, the registry must decide whether to register such cases solely on the basis of the death certificate ('death certificate only', or DCO).
Matching of data files
The registry files may need to be matched against other computer files, either to provide missing data items or for the purposes of research. If it is necessary for such matching to be undertaken outside the registry, e.g. in a vital statistics office or on an external computer, the registry should first ensure that the confidentiality of its records will be preserved by the agency receiving the registry data.
Transmission of information
Authority to transmit identifiable data from the registry, whether by mail (in paper or machine-readable form), by telephone or by electronic means, should be obtained before transmission from the Director or other nominated staff member to whom specific responsibility for such transmission has been delegated. The need for the registry to pass identifiable information to external callers by telephone should be infrequent. One example might be where a clinician requests specific information concerning a patient in the context of managing that patient's disease.
Use of computer
Various physical and electronic measures are available to prevent unauthorised access to information held on the computer. The electronic measures are subject to rapid evolution, and will only be discussed in general terms here.
Data entry
Where feasible, the computer terminal(s) used for data entry may be placed in a separate room, access to which is restricted.
Other precautions may include:
(a) use of user names and passwords which do not appear on the screen when typed;
(b) change of passwords at intervals; (c) automatic logging by the computer of all successful and unsuccessful attempts to enter the system, with regular checks of this log against written records of sessions spent at the terminal by the authorised users. Physicians who request data in the context of treating a patient registered with cancer should be given unrestricted access to the registry's data for that patient.
6.4 Release of identifiable data for research
The cancer registry should consider the release of confidential data only if the request is received in writing, if the nature of the request falls within the accepted range of uses of registry data, and if the request meets the registry's requirements for safeguarding the confidentiality of its data. The request should therefore be expected to include: (a) the exact purpose for which the data are needed; (b) the nature of the information required, and a justification of the need for confidential data; and (c) the name and position of the person(s) who would have access to the confidential data; and (d) the period of time for which the data would be used, and the way in which the data would be disposed of after the elapse of this period.
Release of aggregate data
Aggregate data in tabular or comparable formats (e.g. the numbers of persons registered with a given cancer by age, sex, year, etc) would not normally be subject to constraints on release in relation to confidentiality. For small geographic areas, however, tables containing cells with very few entries could in theory make it possible for individuals to be identified, and the registry should consider suitable measures to avoid this.
6.6 Provision of data to individuals
The cancer registry should not in general inform individuals whether or not there are data about them in the registry, unless required to do so by law: such requests should be referred to the treating physician or to the person responsible for data protection in the treating institution. It is preferable that any information about individuals be divulged through the treating physician, rather than directly to the person concerned. When the study design requires that identifiable data can be transmitted across registry or national borders, and if legislation permits, then such transferred data should remain subject to the same rules of confidentiality as in the registry of origin. Cancer registries participating in such studies should satisfy themselves that their data will be treated accordingly. It may be advisable that data for such studies be transferred to a suitable independent research agency or a reserach centre recognised by the World Health Organization.
News media
Cancer registries are frequently approached by the press for information on cancer. It is recommended that all such enquiries be referred to the Director or other nominated staff member to whom specific responsibility for dealing with the press has been delegated.
Conditions for release of data
The Director of the registry should obtain satisfactory evidence that the intended recipient of data requested for research purposes will: (a) observe the same principles of confidentiality as are observed by the staff of the cancer registry; (b) comply with all restrictions imposed by the registry on the use of the data, in particular that they will not be used for purposes other than those agreed at the time of provision of the data, and that they will not be communicated to other parties; (c) not contact registered persons (or relatives of persons) whose identities have been provided in confidence by the cancer registry (e.g. for research based on interview) except if written authorisation to do this has first been obtained from the treating physician in each case: in some countries the project may also need to be approved by an ethical committee;
(d) ensure that any publication of the results of research will not enable any individual to be identified; and (e) return or destroy in an approved manner all data which are no longer required for the purpose specified in the request.
Guidelines for release of data
It is recommended that registries consider preparing a document which sets out the procedures and criteria applicable to the release of their data, especially the release of identifiable data for research. Such a document could be provided to researchers requesting identifiable data.
Recipients of identifiable data approved under these procedures should also be asked to provide signed commitments to respect the confidentiality of such data and to adhere to the registry's guidelines for the use of the data, including destruction or return of the data on completion of the research.
6.11 Cessation of cancer registration
Each cancer registry should develop a policy for the actions to be taken in the event that the registry ceases operation. Consideration should be given to methods of storage of the registry database in an archive, so as to preserve its utility for the purposes outlined above (section 3.4) whilst ensuring the maintenance of confidentiality. It is recommended that, where possible, a suitable agency be identified, in advance, to store the registry archive for a minimum of 35 years. The agency should undertake to make the database available for the purposes defined by the registry and under the same rules of confidentiality as applied by the registry. Consideration should also be given to the data selected for storage and the method of archiving. Selected paper records might be microfilmed, and selected computer files archived on electronic media. Safe disposal of confidential records not included in an archive deposit should also be planned in advance.
